Butler J. Fonarow G.C. Zile M.R. et al.

Developing therapies for heart failure with preserved ejection fraction: current state and future directions.

JACC Heart Fail. 2: 97-112Oghina S. Bougouin W. Bézard M. et al.

The impact of patients with cardiac amyloidosis in HFpEF trials.

JACC Heart Fail. 9: 169-178Mohammed S.F. Mirzoyev S.A. Edwards W.D. et al.

Left ventricular amyloid deposition in patients with heart failure and preserved ejection fraction.

JACC Heart Fail. 2: 113-122González-López E. Gagliardi C. Dominguez F. et al.

Clinical characteristics of wild-type transthyretin cardiac amyloidosis: disproving myths.

Eur Heart J. 38: 1895-1904

Tanskanen M, Peuralinna T, Polvikoski T, et al. Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation inalpha2-macroglobulinandtau: a population-based autopsy study. Ann Med. 2008;40(3):232-239.

Gillmore J.D. Maurer M.S. Falk R.H. et al.

Nonbiopsy diagnosis of cardiac transthyretin amyloidosis.

Circulation. 133: 2404-2412Sipe J.D. Benson M.D. Buxbaum J.N. et al.

Nomenclature 2014: amyloid fibril proteins and clinical classification of the amyloidosis.

Amyloid. 21: 221-224

Molecular mechanisms of amyloidosis.

N Engl J Med. 349: 583-596Rapezzi C. Merlini G. Quarta C.C. et al.

Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types.

Circulation. 120: 1203-1212

Amyloidosis: a convoluted story: historical review.

Br J Haematol. 114: 529-538

Transthyretin amyloidosis: a little history of hereditary amyloidosis.

Amyloid. 24: 76-77

History of amyloidosis.

J Intern Med. 232: 509-510Gorevic P.D. Prelli F.C. Wright J. et al.

Systemic senile amyloidosis. Identification of a new prealbumin (transthyretin) variant in cardiac tissue: immunologic and biochemical similarity to one form of familial amyloidotic polyneuropathy.

J Clin Invest. 83: 836-843Connors L.H. Lim A. Prokaeva T. et al.

Tabulation of human transthyretin (TTR) variants.

Amyloid. 10: 160-184Falk R.H. Gertz M.A. Benson M.D. et al.

Rationale and Design of a Phase 3 study to evaluate the efficacy and safety of ION-682884 in patients with transthyretin-mediated amyloid cardiomyopathy (ATTR-CM).

Blood. 134: 5764Bandera F. Martone R. Chacko L. et al.

Clinical importance of left atrial infiltration in cardiac transthyretin amyloidosis.

JACC Cardiovasc Imaging. 15: 17-29Connors L.H. Sam F. Skinner M. et al.

Heart failure resulting from age-related cardiac amyloid disease associated with wild-type transthyretin: a prospective, observational cohort study.

Circulation. 133: 282-290Adams D. Koike H. Slama M. et al.

Hereditary transthyretin amyloidosis: a model of medical progress for a fatal disease.

Nat Rev Neurol. 15: 387-404Maurer M.S. Hanna M. Grogan M. et al.

Genotype and phenotype of transthyretin cardiac amyloidosis: THAOS (transthyretin amyloid outcome Survey).

J Am Coll Cardiol. 68: 161-172Suhr O.B. Svendsen I.H. Andersson R. et al.

Hereditary transthyretin amyloidosis from a Scandinavian perspective.

J Intern Med. 254: 225-235Jacobson D.R. Pastore R.D. Yaghoubian R. et al.

Variant-sequence transthyretin (isoleucine 122) in late-onset cardiac amyloidosis in black Americans.

N Engl J Med. 336: 466-473Booth D.R. Booth S.E. Persey M.R. et al.

Three new amyloidogenic TTR mutations: PRO12, GLU18, and VAL33. Neuromuscular Disord. Three new amyloidogenic TTR mutations: PRO12, GLU18, and VAL33 Neuromuscular Disord.

. 6Reynolds M.M. Veverka K.K. Gertz M.A. et al.

Ocular manifestations of familial transthyretin amyloidosis.

Am J Ophthalmol. 183: 156-162Kittleson M.M. Maurer M.S. Ambardekar A.V. et al.

Cardiac amyloidosis: evolving diagnosis and management: a scientific statement from the American heart association.

Circulation. 142: e7-e22Quarta C.C. Buxbaum J.N. Shah A.M. et al.

The amyloidogenic V122I transthyretin variant in elderly black Americans.

N Engl J Med. 372: 21-29Grogan M. Scott C.G. Kyle R.A. et al.

Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system.

J Am Coll Cardiol. 68: 1014-1020Gillmore J.D. Damy T. Fontana M. et al.

A new staging system for cardiac transthyretin amyloidosis.

Eur Heart J. 39: 2799-2806Cheng R.K. Levy W.C. Vasbinder A. et al.

Diuretic dose and NYHA functional class are independent predictors of mortality in patients with transthyretin cardiac amyloidosis.

JACC Cardiooncol. 2: 414-424Sperry B.W. Reyes B.A. Ikram A. et al.

Tenosynovial and cardiac amyloidosis inpatients undergoing carpal tunnel release.

J Am Coll Cardiol. 72: 2040-2050Geller H.I. Singh A. Alexander K.M. et al.

Association between ruptured distal biceps tendon and wild-type transthyretin cardiac amyloidosis.

JAMA. 318: 962Westermark P. Westermark G.T. Suhr O.B. et al.

Transthyretin-derived amyloidosis: probably a common cause of lumbar spinal stenosis.

Ups J Med Sci. 119: 223-228Castaño A. Narotsky D.L. Hamid N. et al.

Unveiling transthyretin cardiac amyloidosis and its predictors among elderly patients with severe aortic stenosis undergoing transcatheter aortic valve replacement.

Eur Heart J. 38: 2879-2887Scully P.R. Treibel T.A. Fontana M. et al.

Prevalence of cardiac amyloidosis in patients referred for transcatheter aortic valve replacement.

J Am Coll Cardiol. 71: 463-464Ternacle J. Krapf L. Mohty D. et al.

Aortic stenosis and cardiac amyloidosis: JACC review topic of the week.

J Am Coll Cardiol. 74: 2638-2651Galat A. Guellich A. Bodez D. et al.

Aortic stenosis and transthyretin cardiac amyloidosis: the chicken or the egg?.

Eur Heart J. 37: 3525-3531Longhi S. Lorenzini M. Gagliardi C. et al.

Coexistence of degenerative aortic stenosis and wild-type transthyretin-related cardiac amyloidosis.

JACC Cardiovasc Imaging. 9: 325-327Treibel T.A. Fontana M. Gilbertson J.A. et al.

Occult transthyretin cardiac amyloid in severe Calcific aortic stenosis: prevalence and prognosis in patients undergoing Surgical aortic valve replacement.

Circ Cardiovasc Imaging. 9: e005066Nativi-Nicolau J. Maurer M.S.

Amyloidosis cardiomyopathy: update in the diagnosis and treatment of the most common types.

Curr Opin Cardiol. 33: 571-579Kyriakou P. Mouselimis D. Tsarouchas A. et al.

Diagnosis of cardiac amyloidosis: a systematic review on the role of imaging and biomarkers.

BMC Cardiovasc Disord. 18: 221Cyrille N.B. Goldsmith J. Alvarez J. et al.

Prevalence and prognostic significance of low QRS voltage among the three main types of cardiac amyloidosis.

Am J Cardiol. 114: 1089-1093

Amyloid cardiomyopathy.

Herz. 45: 267-271Di Nunzio D. Recupero A. de Gregorio C. et al.

Echocardiographic findings in cardiac amyloidosis: inside two-dimensional, Doppler, and strain imaging.

Curr Cardiol Rep. 21https://doi.org/10.1007/s11886-019-1094-zMaurer M.S. Elliott P. Comenzo R. et al.

Addressing common questions encountered in the diagnosis and management of cardiac amyloidosis.

Circulation. 135: 1357-1377Carvalho FP de Erthal F. Azevedo C.F.

The role of cardiac MR imaging in the assessment of patients with cardiac amyloidosis.

Magn Reson Imaging Clin N Am. 27: 453-463Fontana M. Banypersad S.M. Treibel T.A. et al.

Native T1 mapping in transthyretin amyloidosis.

JACC Cardiovasc Imaging. 7: 157-165Bokhari S. Castaño A. Pozniakoff T. et al.

(99m)Tc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses.

Circ Cardiovasc Imaging. 6: 195-201Glaudemans A.W.J.M. van Rheenen R.W.J. van den Berg M.P. et al.

Bone scintigraphy with99mtechnetium-hydroxymethylene diphosphonate allows early diagnosis of cardiac involvement in patients with transthyretin-derived systemic amyloidosis.

Amyloid. 21: 35-44Quarta C.C. Gonzalez-Lopez E. Gilbertson J.A. et al.

Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis.

Eur Heart J. 38: 1905-1908Ansari-Lari M.A. Ali S.Z.

Fine-needle aspiration of abdominal fat pad for amyloid detection: a clinically useful test?.

Diagn Cytopathol. 30: 178-181Fine N.M. Arruda-Olson A.M. Dispenzieri A. et al.

Yield of noncardiac biopsy for the diagnosis of transthyretin cardiac amyloidosis.

Am J Cardiol. 113: 1723-1727Bulawa C.E. Connelly S. Devit M. et al.

Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade.

Proc Natl Acad Sci U S A. 109: 9629-9634Maurer M.S. Bokhari S. Damy T. et al.

Expert consensus recommendations for the suspicion and diagnosis of transthyretin cardiac amyloidosis.

Circ Heart Fail. 12: e006075

Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis.

Chest. 104: 618-620Gertz M.A. Skinner M. Connors L.H. et al.

Selective binding of nifedipine to amyloid fibrils.

Am J Cardiol. 55: 1646Bozkurt B. Colvin M. Cook J. et al.

Current diagnostic and treatment strategies for specific dilated cardiomyopathies: a scientific statement from the American heart association.

Circulation. 134https://doi.org/10.1161/cir.0000000000000455Donnelly J.P. Sperry B.W. Gabrovsek A. et al.

Digoxin use in cardiac amyloidosis.

Am J Cardiol. 133: 134-138Ritts A.J. Cornell R.F. Swiger K. et al.

Current concepts of cardiac amyloidosis: diagnosis, clinical management, and the need for collaboration.

Heart Fail Clin. 13: 409-416Sperry B.W. Hanna M. Shah S.J. et al.

Spironolactone in patients with an echocardiographic HFpEF phenotype suggestive of cardiac amyloidosis: results from TOPCAT.

JACC Heart Fail. 9: 795-802Mints Y.Y. Doros G. Berk J.L. et al.

Features of atrial fibrillation in wild-type transthyretin cardiac amyloidosis: a systematic review and clinical experience: atrial fibrillation in wild-type transthyretin amyloidosis.

ESC Heart Fail. 5: 772-779El-Am E.A. Dispenzieri A. Melduni R.M. et al.

Direct current cardioversion of atrial arrhythmias in adults with cardiac amyloidosis.

J Am Coll Cardiol. 73: 589-597Dli F. Syed I.S. Martinez M. et al.

Intracardiac thrombosis and embolism in patients with cardiac amyloidosis.

Circulation. 119: 2490-2497Barbhaiya C.R. Kumar S. Baldinger S.H. et al.

Electrophysiologic assessment of conduction abnormalities and atrial arrhythmias associated with amyloid cardiomyopathy.

Heart Rhythm. 13: 383-390Longhi S. Quarta C.C. Milandri A. et al.

Atrial fibrillation in amyloidotic cardiomyopathy: prevalence, incidence, risk factors and prognostic role.

Amyloid. 22: 147-155Towbin J.A. McKenna W.J. Abrams D.J. et al.

2019 HRS expert consensus statement on evaluation, risk stratification, and management of arrhythmogenic cardiomyopathy.

Heart Rhythm. 16: e301-e372Donnellan E. Wazni O. Kanj M. et al.

Atrial fibrillation ablation in patients with transthyretin cardiac amyloidosis.

Europace. 22: 259-264Kochav S.M. Dizon J. Maurer M.S.

A peak into the pace of cardiac amyloidosis.

JACC Clin Electrophysiol. 6: 1155-1157Donnellan E. Wazni O.M. Saliba W.I. et al.

Cardiac devices in patients with transthyretin amyloidosis: impact on functional class, left ventricular function, mitral regurgitation, and mortality.

J Cardiovasc Electrophysiol. 30: 2427-2432Giancaterino S. Urey M.A. Darden D.

Hsu management of arrhythmias in cardiac amyloidosis.

J Am Coll Cardiol. 6: 351-361Lin G. Dispenzieri A. Kyle R. et al.

Implantable cardioverter defibrillators in patients with cardiac amyloidosis: ICD in cardiac amyloidosis.

J Cardiovasc Electrophysiol. 24: 793-798

Rehorn MR, Loungani RS, Black-Maier E, et al. Cardiac Implantable Electronic Devices: A Window Into the Evolution of Conduction Disease in Cardiac Amyloidosis. JACC Clin Electrophysiol 2020:6(9):1144-1154. doi:10.1016/j.jacep.2020.04.020. Epub 2020 Aug 26. PMID: 32972550.

Judge D.P. Heitner S.B. Falk R.H. et al.

Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy.

J Am Coll Cardiol. 74: 285-295Ibrahim M. Saint Croix G.R. Lacy S. et al.

The use of diflunisal for transthyretin cardiac amyloidosis: a review.

Heart Fail Rev. https://doi.org/10.1007/s10741-021-10143-4Benson M.D. Waddington-Cruz M. Berk J.L. et al.

Inotersen treatment for patients with hereditary transthyretin amyloidosis.

N Engl J Med. 379: 22-31Suhr O.B. Coelho T. Buades J. et al.

Efficacy and safety of patisiran for familial amyloidotic polyneuropathy: a phase II multi-dose study.

Orphanet J Rare Dis. 10: 109Gillmore J.D. Gane E. Taubel J. et al.

CRISPR-Cas9 in vivo gene editing for transthyretin amyloidosis.

N Engl J Med. 385: 493-502Griffin J.M. Rosenblum H. Maurer M.S.

Pathophysiology and therapeutic approaches to cardiac amyloidosis.

Circ Res. 128: 1554-1575Berk J.L. Suhr O.B. Obici L. et al.

Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial.

JAMA. 310: 2658Adams D. Gonzalez-Duarte A. O’Riordan W.D. et al.

Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis.

N Engl J Med. 379: 11-21Maurer M.S. Schwartz J.H. Gundapaneni B. et al.

Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy.

N Engl J Med. 379: 1007-1016Elliott P. Drachman B.M. Gottlieb S.S. et al.

Long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy.

Circ Heart Fail. 15: e008193